文献速递白血病

达沙替尼治疗慢性髓性白血病并发症的发生率与自然史

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.
PubMed 文献 · Blood Adv · 2017-05-15

该回顾性研究纳入澳大利亚17家机构的212例慢性期慢性髓性白血病患者,评估达沙替尼不良事件的发生率与自然史。116例(55%)报告不良事件,最常见为胸腔积液(53例,25%),是永久停药的主要原因;年龄和剂量为胸腔积液的危险因素(P<.01和.047)。5%发生肺动脉高压,7例中6例停药后可逆;减量和暂时停药对分子学缓解率影响极小。

要点

  • 胸腔积液发生率25%,是永久停药的主要原因,年龄和剂量为危险因素(P<.01和.047)。
  • 发生胸腔积液者6个月后更易达MR4.5(P=.008);减量后复发率低于维持100mg者(P=.041),但50mg仍可复发。
  • 肺动脉高压发生率5%,常伴胸腔积液,7例中6例停药后可逆;减量和暂时停药对分子学缓解影响极小。

核心结论

  • 作者认为,对老年患者使用最低有效剂量以降低积液风险、对血细胞减少进行剂量调整并谨慎联用抗血小板治疗,免疫健全患者因毒性永久停用达沙替尼的可能性很小。

研究设计与样本

  • 回顾性研究,纳入澳大利亚17家机构的212例慢性期慢性髓性白血病患者,评估达沙替尼不良事件的发生率与自然史。

主要发现

  • 116例(55%)报告不良事件,最常见为胸腔积液(53例,25%),是永久停药的主要原因。
  • 年龄和剂量为胸腔积液的危险因素(P<.01和.047)。
  • 维持100mg者胸腔积液复发率高于减量者(P=.041),但50mg时仍可复发。
  • 发生胸腔积液者6个月后达MR4.5的可能性高于无积液者(P=.008)。
  • 肺动脉高压发生率为5%,常伴胸腔积液,7例中6例停药后可逆;减量和暂时停药对分子学缓解率影响极小。

临床怎么用

  • 作者认为,对老年患者使用最低有效剂量以降低积液风险、对血细胞减少进行剂量调整并谨慎联用抗血小板治疗,免疫健全患者因毒性永久停用达沙替尼的可能性很小。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dasatinib has shown superiority over imatinib in achieving molecular responses (MRs) in chronic phase chronic myeloid leukemia but with a different toxicity profile, which may impact its overall benefit. Reported toxicities include pleural effusions and pulmonary hypertension, and although the incidence of these events is well described, response to therapy and impact of dose modifications on toxicity has not been comprehensively characterized in a real-world setting. We retrospectively reviewed the incidence of dasatinib adverse events in 212 chronic phase chronic myeloid leukemia patients at 17 Australian institutions. Adverse events were reported in 116 patients (55%), most commonly pleural effusions (53 patients, 25%), which was the predominant cause of permanent drug cessation. Age and dose were risk factors for pleural effusion (P < .01 and .047, respectively). Recurrence rates were higher in those who remained on 100 mg compared with those who dose reduced (P = .041); however, recurrence still occurred at 50 mg. Patients who developed pleural effusions were more likely to have achieved MR4.5 after 6 months of dasatinib than those without effusions (P = .008). Pulmonary hypertension occurred in 5% of patients, frequently in association with pleural effusion, and was reversible upon dasatinib cessation in 6 of 7 patients. Dose reductions and temporary cessations had minimal impact on MR rates. Our observations suggest that by using the lowest effective dose in older patients to minimize the effusion risk, dose modification for cytopenias, and care with concomitant antiplatelet therapy, the necessity for permanent dasatinib cessation due to toxicity is likely to be minimal in immunologically competent patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fox LC, Cummins KD, Costello B, et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv. 2017. PMID: 29296724. doi:10.1182/bloodadvances.2016003889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。